Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL · Alpha
██.█% Sign up free to reveal

Hutchmed (China) Ltd (HCM) AI Forecast

Our AI analyzed Hutchmed (China) Ltd. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$HCM Neutral Signal Full forecast available
Sign Up Free

Hutchmed (China) Ltd (HCM) Stock Forecast Sept. 24, 2026

Hutchmed (China) Ltd (HCM) AI Stock Price Forecast & Investment Analysis

Hutchmed (China) Ltd Stock Price Chart and Technical Analysis

Loading chart...

Hutchmed (China) Ltd (HCM) - Comprehensive Stock Analysis & Investment Research

Deep dive into Hutchmed (China) Ltd's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 24, 2026 (UTC)

Hutchmed (China) Ltd Investment Summary

When evaluating whether Hutchmed (China) Ltd (HCM) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Hutchmed (China) Ltd (HCM) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry. . With a market capitalization of $13 billion, the company is a large-cap stock offering relative stability combined with growth potential.

Financial Performance Analysis

Our comprehensive financial analysis covers Hutchmed (China) Ltd's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Hutchmed (China) Ltd along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Hutchmed (China) Ltd is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Hutchmed (China) Ltd

Sign Up Free
Corporate Identity

Hutchmed (China) Ltd (Stock Symbol: HCM) is a prominent company operating within the Life Sciences sector, with a specific focus on the Pharmaceutical Preparations industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Hutchmed (China) Ltd's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Hutchmed (China) Ltd...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Hutchmed (China) Ltd...

Unlock Full Company Profile

Get complete details about Hutchmed (China) Ltd

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Hutchmed (China) Ltd...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Hutchmed (China) Ltd...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Hutchmed (China) Ltd...

Unlock Financial Analysis

Get complete financial metrics for Hutchmed (China) Ltd

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Hutchmed (China) Ltd's AI Price Forecast

Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

4537 Stocks in the out-of-sample test
73.7% Rebalance periods with a positive net return
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Hutchmed (China) Ltd strategically competes in the highly dynamic Pharmaceutical Preparations marketplace. As a large-cap market participant, the company has established significant competitive advantages and market presence. Large-cap companies typically benefit from brand recognition, operational scale, diverse revenue streams, and the financial resources to invest in research and development, marketing, and strategic acquisitions. This size category attracts substantial institutional ownership and analyst coverage.

Industry Competitive Landscape

Hutchmed (China) Ltd competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Financial Strength & Leverage

Current ratio of 4.96 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Hutchmed (China) Ltd (HCM) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Hutchmed (China) Ltd stock analysis.

Deep dive into Hutchmed (China) Ltd's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Hutchmed (China) Ltd stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Hutchmed (China) Ltd:

P/B Ratio 10.13x
Market Cap $12.54B
EPS $0.56
Book Value/Share $1.42
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Hutchmed (China) Ltd converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Hutchmed (China) Ltd: An ROE of 40.0% demonstrates excellent shareholder value creation.

ROE 40.0%
ROA 28.2%
ROIC -5.8%
Operating Margin -7.0%
Net Margin 42.0%
EBT Margin 48.1%
Tax Rate 12.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Hutchmed (China) Ltd's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Hutchmed (China) Ltd: A current ratio of 4.96 indicates strong liquidity.

Current Ratio 4.96x
Quick Ratio 4.83x
D/E Ratio 0.41x
Financial Leverage 1.42x
Interest Coverage -14.2x
Working Capital $1.25B
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Hutchmed (China) Ltd's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Hutchmed (China) Ltd:

Operating Cash Flow -$64M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Hutchmed (China) Ltd uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Hutchmed (China) Ltd:

Understanding Financial Statement Data

What these metrics mean: Key figures from Hutchmed (China) Ltd's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Hutchmed (China) Ltd:

Income Statement
Operating Income -$82M
Net Income $494M
R&D Expense $360M
SG&A Expense $216M
Balance Sheet Highlights (USD millions)
Total Current Assets $1.57B (89.4% of assets)
Cash & Short-term Investments $71M (4.1% of assets)
Accounts Receivable $127M (7.2% of assets)
Inventory $41M (2.3% of assets)
Total Liabilities $502M (28.6% of assets)
Short-term Debt $270M (15.4% of assets)
Dividend & Shareholder Information
Shares Outstanding 872M

Latest Hutchmed (China) Ltd Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Hutchmed (China) Ltd (HCM) stock price and investment outlook.

More news available

Sign up free to read all 9 news articles and stay updated on market developments.

Sign Up Free to Read More

Where HCM sits on the market map

Explore the map →

Hutchmed (China) Ltd Industry Peers - Pharmaceutical Preparations

Companies classified under the same SEC industry code as Hutchmed (China) Ltd (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Company Ticker Symbol 90-Day AI Forecast (Alpha) Market Cap (USD M) P/E Ratio P/B Ratio
HCM ██% $12.54B x 10.1x
LLY ██% $1.08T 40.6x 110.2x
JNJ ██% $648.67B 30.8x 7.6x
ONC ██% $539.52B x 104.3x
ABBV ██% $468.43B 74.2x x
MRK ██% $365.34B 115.1x 8.7x
NVS ██% $272.31B x x
GSK ██% $214.26B x x
ABT ██% $180.26B 28.6x 3.5x
PFE ██% $160.62B 37.1x 1.9x
VRTX ██% $130.87B 29.7x 6.5x
BMY ██% $125.63B 13.5x 5.6x
REGN ██% $82.55B 19.1x 2.6x
SNY ██% $50.80B x x
TEVA ██% $45.46B 64.3x 5.9x
ALNY ██% $33.40B x 24.7x
RPRX ██% $33.15B 40.7x 4.9x
ATHE ██% $32.40B x x
TAK ██% $29.93B x x
ZLAB ██% $29.68B x 48.9x
ZTS ██% $29.59B 11.3x 9.4x
ROIV ██% $26.60B x 6.3x
INSM ██% $25.84B x 34.1x
UTHR ██% $20.99B 16.0x 3.3x
VTRS ██% $19.66B x x
JAZZ ██% $15.25B 16.2x 3.2x
ASND ██% $14.30B x x
SMMT ██% $13.12B x 20.8x
BBIO ██% $12.96B x x
CORT ██% $12.81B x 18.2x
BMRN ██% $11.88B x 1.9x
KNSA ██% $11.87B x 19.6x
MDGL ██% $11.85B x 22.6x
ELAN ██% $11.17B x 1.7x
RDY ██% $10.34B x x
AXSM ██% $10.27B x 123.3x
ARWR ██% $9.33B x 20.1x
CYTK ██% $9.13B x x
PTGX ██% $8.98B x 10.7x
PRAX ██% $7.88B x 5.9x
SYRE ██% $7.77B x 7.1x
GPCR ██% $7.71B x 5.7x
ABVX ██% $7.39B x x
IONS ██% $7.30B x 16.6x
ALKS ██% $6.84B x 3.8x
LEGN ██% $6.82B x x
RYTM ██% $6.76B x 65.7x
BLRX ██% $6.68B x x
BLTE ██% $6.67B x 8.7x
AMRX ██% $6.32B x x
LQDA ██% $6.04B x 31.0x
LGND ██% $5.95B 30.2x 6.2x
MIRM ██% $5.80B x x
AMRN ██% $5.64B x 12.7x
TVTX ██% $5.64B x 230.0x
COGT ██% $5.45B x 10.2x
PTCT ██% $5.20B x x
ERAS ██% $5.08B x 14.0x
DNTH ██% $5.07B x 4.3x
VKTX ██% $4.86B x 11.9x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Hutchmed (China) Ltd Stock Forecast

How accurate are Hutchmed (China) Ltd stock predictions?

A per-ticker accuracy statistic for HCM is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

What factors influence Hutchmed (China) Ltd stock price forecasts?

Our analysis considers Hutchmed (China) Ltd's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Hutchmed (China) Ltd a good investment in 2026?

Based on our AI analysis, Hutchmed (China) Ltd shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Hutchmed (China) Ltd forecasts updated?

Hutchmed (China) Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 24, 2026.

Want a simpler view of Hutchmed (China) Ltd?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...